mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Withdrawn before enrolling · Phase 1
Conditions studied: Relapsed or Refractory Multiple Myeloma
In brief
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
Key facts
- Study ID
- NCT05918250
- Run by
- ModernaTX, Inc.
- People needed
- 0
- Starts
- 2023-08-15
- Expected to finish
- 2026-05-27
- Last updated by the study team
- 2023-08-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UAB Hospital — Birmingham, Alabama, United States
- Washington University Medical Center — St Louis, Missouri, United States
- University of Miami Health System — Miami, Florida, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- The Mount Sinai Hospital — New York, New York, United States
- Ohio State University Hospital — Columbus, Ohio, United States
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- UW Medical Center — Seattle, Washington, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
- Hôpital Maisonneuve-Rosemont — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.